Alnylam Pharmaceuticals (ALNY) EBT (2009 - 2026)

Alnylam Pharmaceuticals' EBT history runs 18 years deep, the most recent figure standing at $221.7 million for Q1 2026.

• Quarterly EBT rose 9460.35% year-over-year to $221.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $553.1 million (up 274.95% YoY) and the FY2025 annual result came in at $323.2 million, up 185.63% from the prior year.
• EBT was $221.7 million for Q1 2026 at Alnylam Pharmaceuticals, up from $86.3 million in the prior quarter.
• Across five years, EBT topped out at $280.6 million in Q3 2025 and bottomed at -$405.9 million in Q3 2022.
• A 5-year average of -$81.6 million and a median of -$108.7 million in 2024 frame the typical range for EBT.
• Annual changes were most pronounced in 2025 — EBT slumped 216.63% — and 2026, when it jumped 9460.35%.
• Alnylam Pharmaceuticals' EBT stood at -$207.0 million in 2022, then surged by 33.49% to -$137.7 million in 2023, then slumped by 40.87% to -$194.0 million in 2024, then soared by 144.47% to $86.3 million in 2025, then surged by 156.96% to $221.7 million in 2026.
• Business Quant data shows ALNY's EBT at $221.7 million in Q1 2026, $86.3 million in Q4 2025, and $280.6 million in Q3 2025.